IMCC Stock Analysis: Buy, Sell, or Hold?
IMCC - IM Cannabis Corp. Common Shares
$0.88
-0.05 (-5.08%)
▼
5d:
-36.86%
30d:
-72.4%
90d:
+717.23%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When IMCC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IMCC is down 36.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IMCC is down 36.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IMCC is currently trading at $0.88, which is considered oversold relative to its 30-day fair value range of $1.18 to $2.86.
Technical Outlook: Technically, IMCC is in a strong uptrend. Immediate support is located at $0.80, while resistance sits at $1.59. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: IMCC scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.22 (+836.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMCC is in a strong uptrend. Immediate support is located at $0.80, while resistance sits at $1.59. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: IMCC scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.22 (+836.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.18 -
$2.86
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.1%)
- BULLISH: Trading 836.7% below Wall St target ($8.22)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.18 -
$2.86
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.80
Resistance Level
$1.59
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
42.37
Wall Street Target
$8.22
(+836.7%)
Revenue Growth (YoY)
-40.2%
Profit Margin
-39.1%
Share & Embed Analysis
Last updated: October 24, 2026 4:12 AM ET
Data refreshes hourly during market hours. Next update: 5:12 AM
Data refreshes hourly during market hours. Next update: 5:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMCC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
